Overexpression of ubiquitin-specific protease 22 predicts poor survival in patients with early-stage non-small cell lung cancer

  • J. Ning The Third Affiliated Hospital of Harbin Medical University, China.
  • J. Zhang The Third Affiliated Hospital of Harbin Medical University, China.
  • W. Liu The Third Affiliated Hospital of Harbin Medical University, China.
  • Y. Lang The Third Affiliated Hospital of Harbin Medical University, China.
  • Y. Xue The Third Affiliated Hospital of Harbin Medical University, China.
  • S. Xu | shidong_xu@163.com The Third Affiliated Hospital of Harbin Medical University, China.

Abstract

Ubiquitin-specific protease 22 (USP22), a novel ubiquitin hydrolase, has been implicated in oncogenesis and cancer progression in various types of human cancer. However, the clinical significance of USP22 expression in non-small cell lung cancer (NSCLC) has not been determined. In the present study, USP22 messenger RNA (mRNA) and protein levels were analyzed by quantitative real-time polymerase chain reaction (PCR) and western blot analysis in 30 cases of NSCLC and in corresponding non-tumor tissue samples. Furthermore, immunohistochemistry was performed to detect USP22 protein expression in 86 primary tumor tissues derived from clinically annotated NSCLC cases at stage I-II. In our analysis we found that both USP22 mRNA and protein levels in NSCLC tissues were significantly higher than those in corresponding non-tumor tissues and that there was a significant correlation between the expression of USP22 mRNA and protein (P=0.000, κ=0.732). In addition, a high-level of USP22 expression was observed in 53.3% (39 out of 86) cases and it was correlated with large tumor size (P=0.029) and lymph node metastasis (P=0.026). Patients with tumors displaying a high-level of USP22 expression showed significantly shorter survival (P=0.006, log-rank test). Importantly, multivariate analysis showed that high USP22 protein expression was an independent prognostic factor for NSCLC patients (P=0.003). In sum, our data suggest that USP22 plays an important role in NSCLC progression at the early stage, and that overexpression of USP22 in tumor tissues could be used as a potential prognostic marker for patients with early clinical stage of NSCLC.

Downloads

Download data is not yet available.

Author Biographies

J. Ning, The Third Affiliated Hospital of Harbin Medical University
Department of Thoracic Surgery
J. Zhang, The Third Affiliated Hospital of Harbin Medical University
Department of Thoracic Surgery
W. Liu, The Third Affiliated Hospital of Harbin Medical University
Fourth Department of Internal Medicine
Y. Lang, The Third Affiliated Hospital of Harbin Medical University
Department of Thoracic Surgery
Y. Xue, The Third Affiliated Hospital of Harbin Medical University
Department of Gastrointestinal Surgery
S. Xu, The Third Affiliated Hospital of Harbin Medical University
Department of Thoracic Surgery
Published
2012-11-30
Section
Original Papers
Keywords:
Ubiquitin-specific protease 22, nonsmall cell lung cancer, prognosis.
Statistics
Abstract views: 777

PDF: 226
HTML: 497
Share it

PlumX Metrics

PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

How to Cite
Ning, J., Zhang, J., Liu, W., Lang, Y., Xue, Y., & Xu, S. (2012). Overexpression of ubiquitin-specific protease 22 predicts poor survival in patients with early-stage non-small cell lung cancer. European Journal of Histochemistry, 56(4), e46. https://doi.org/10.4081/ejh.2012.e46